10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 5 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Deferasirox (ICL-670) Deferasirox (ICL-670, CGP-72670) is an iron chelator , also a cytochrome P450 3A4 inducer, Cytochrome P450 2C8 inhibitor , and Cytochrome P450 1A2 inhibitor. Deferasirox-induced iron depletion promotes BclxL downregulation and cell
In vitro
Deferasirox effectively chelates iron from Rhizopus oryzae and demonstrates cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. Deferasirox incubation induces a significant inhibition of NF-κB activity and a cytoplasmic sequestration of its active subunit p65 in an inactive form in 28 of 40 peripheral blood samples. Deferasirox inhibits three human myeloid cell lines (K562, U937, and HL60) with IC50 of 17-50 mM. Deferasirox is cidal in vitro against A. fumigatus, with an MIC and MFC of 25 and 50 mg/L, respectively.
In vivo
Deferasirox significantly improves survival and decreased tissue fungal burden in diabetic ketoacidotic or neutropenic mice with mucormycosis, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhances the host inflammatory response to mucormycosis. Deferasirox synergistically improves survival and reduces tissue fungal burden when combined with liposomal amphotericin B. Deferasirox administered p.o. to rats is absorbed to at least 75%, and the bioavailability is 26%.Deferasirox is present in the blood circulation mainly in the unchanged form and as its iron complex, Fe(deferasirox)2, after intravenous and p.o. administration. Deferasirox is 99.2% bound to plasma proteins. Deferasirox monotherapy modestly prolongs survival of mice with IPA.
Cell Data
cell lines：
Concentrations：
Incubation Time：
Powder Purity:≥99%
| ALogP | 3.8 |
|---|
| Isomeric SMILES | C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O |
|---|---|
| Molecular Weight | 373.36 |
| Reaxy-Rn | 8442898 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=8442898&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Melt Point(°C) | 262 °C |
|---|
| 1. Liu Peng, Wang Qiang, Li Kuan, Bi Bo, Wen Ying-Fei, Qiu Miao-Juan, Zhao Jing, Li Bin-Bin, Zhang Chang-Hua, He Yu-Long. (2022) A DFX-based iron nanochelator for cancer therapy. Frontiers in Bioengineering and Biotechnology, [PMID:36518196] [10.3389/fbioe.2022.1078137] |
| 2. Chen-Fang Miao, Xian-Zhong Guo, Xin-Tian Zhang, Yin-Ning Lin, Wen-Di Han, Zheng-Jun Huang, Shao-Huang Weng. (2021) Ratiometric fluorescence assay based on carbon dots and Cu2+-catalyzed oxidation of O-phenylenediamine for the effective detection of deferasirox. RSC Advances, 11 (55): (34525-34532). [PMID:35494749] [10.1039/D1RA07078A] |
| 3. Wendi Han, Chenfang Miao, Xintian Zhang, Yinning Lin, Xiaoli Hao, Zhengjun Huang, Shaohuang Weng, Xinhua Lin, Xianzhong Guo, Jianyong Huang. (2021) A signal-off fluorescent strategy for deferasirox effective detection using carbon dots as probe and Cu2+ as medium. ANALYTICA CHIMICA ACTA, [PMID:34535261] [10.1016/j.aca.2021.338853] |
| 4. Hongting Liu, Xichu Zhang, Fangchun Ding, Jingfang Pan, Hanxiang Zhu, Zhanwei Zhou, Minjie Sun. (2025) YTHDF1-targeting nanoassembly reverses tumoral immune evasion through epigenetics and cell cycle modulation. JOURNAL OF CONTROLLED RELEASE, [PMID:40010410] [10.1016/j.jconrel.2025.02.070] |
| 5. Zhengning Yang, Zhongxuan Meng, Shangyuan Liu, Yuxin Chen, Xuhong Gan, Zi‑Mei Zhang, Xiaoshan Luo, Jiahong Yan, Huijin Chen, Danqing Huang, Lihong Huang, Xiaomin Zeng, Wenyu Ma, Jun Liu, Linlin Wang, Haotian Huang, Xinyi Yang, Mei Hu, Lin Chen, Hongli Du, Qibin Leng, Li Qiu, Xiaoling Wang. (2025) LTO1 and YAE1 regulate MHC-I expression via nonsense-mediated RNA decay in tumor cells. Journal for ImmunoTherapy of Cancer, 13 (9): (e011893). [PMID:40987494] [10.1136/jitc-2025-011893] |
